Skip to main content
. Author manuscript; available in PMC: 2017 Jan 1.
Published in final edited form as: Ann N Y Acad Sci. 2015 Apr 2;1364(1):62–73. doi: 10.1111/nyas.12750

Figure 2.

Figure 2

PTH treatment failed to inhibit sclerostin/Sost expression in osteocyte in LRP6-deficient mice. (A) Representative images of immunohistochemical staining with an antibody to sclerostin (brown) in 3-month-old male WT and KO mice treated with vehicle or PTH1–34 daily at 80 mg/kg bw, 5 days a week for 4 weeks. Scale bars: 50 μm. (B) Quantification of sclerostin+ osteocytes out of total osteocytes. (C) qRT-PCR analysis of Sost expression in cortical bone extracts from 3-month-old male WT and KO mice treated with vehicle or PTH. For all the experiments, a total of three femur sections from each mouse, and six mice per treatment group were analyzed. *P < 0.05, **P < 0.01.